SPI-Bio has signed a three-year contract that allows it to sell Aterovax's sPLA2 activity test to academic and research laboratories in Europe for research use.
The phospholipases A2 (PLA2) superfamily of enzymes plays a key role in the inflammatory process by generating chemical intermediates.
The activity of secretory PLA2 (sPLA2) is associated with the rupture of the atherosclerotic plaque and the subsequent risk of cardiovascular events.
In research, Aterovax's sPLA2 activity test offers considerable promises for investigating cardiovascular and inflammation diseases, screening drug candidates as well as elucidating their mechanism of action.
'While sPLA2 is not a new molecule, it was really interesting to see that it became a new biomarker in the light of the validation work performed by Aterovax.
'This assay not only supplements our existing range in the field of metabolic diseases, but also complies with our policy to market fully validated kit in the appropriate biological samples,' said Xavier Morge, managing director of SPI-Bio.
